AA-FENO-SUPER TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

FENOFIBRATE

Mevcut itibaren:

AA PHARMA INC

ATC kodu:

C10AB05

INN (International Adı):

FENOFIBRATE

Doz:

200MG

Farmasötik formu:

TABLET

Kompozisyon:

FENOFIBRATE 200MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

FRIBIC ACID DERIVATIVES

Ürün özeti:

Active ingredient group (AIG) number: 0118895001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2021-08-17

Ürün özellikleri

Page 1 of 38
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AA-FENO-SUPER
FENOFIBRATE TABLETS
HOUSE STANDARD
100 MG, 160 MG AND 200 MG
LIPID METABOLISM REGULATOR
AA PHARMA INC.
DATE OF REVISION:
1165 CREDITSTONE ROAD UNIT #1
AUGUST 13, 2021
VAUGHAN, ONTARIO
L4K 4N7
CONTROL # 254380
Page 2 of 38
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................................
8
DRUG INTERACTIONS
........................................................................................................................................
12
DOSAGE AND ADMINISTRATION
....................................................................................................................
16
OVERDOSAGE
......................................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................................
17
STORAGE AND STABILITY
................................................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................